July 9, 2020 -- Pfizer has pledged $100 million to the Antimicrobial Resistance (AMR) Action Fund to address the need for new antibiotics due to the rapid rise of antibiotic-resistant infections.
The AMR Action Fund is a collaboration among over 40 biopharmaceutical companies with the goal of bringing two to four new antibiotics to the clinic by 2030 through partnerships with pharmaceutical companies, philanthropies, development banks, and multilateral organizations.
The new commitment builds on Pfizer's existing work to address AMR through the development of vaccines that reduce the need for antibiotics, active research in anti-infectives, and work with clinical partners to close gaps in infectious disease treatments. The company also manages Atlas, a public access platform for antifungal and antibacterial resistance data.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
